Protea Biosciences Group, Inc. (“Protea”), a leading bioanalytics technology company, announces that Stephen Turner, the company’s CEO, presented at the 15th Annual Needham & Co. Growth Conference on Tuesday January 15, at the Palace Hotel in New York City. Mr. Turner will be discussing the Company’s groundbreaking LAESI technology platform and how the company is building a new life science franchise by offering technologies that allow biologists to obtain full mass spectrometry imaging datasets on their tissue, cell or biofluid samples without sample preparation, as well as to study biodynamics in living colonies.
“We are honored to be presenting at the Needham Growth Conference, which features emerging growth companies such as Protea,” stated Stephen Turner, CEO. “We look forward to highlighting our commercial progress, and the large market opportunity for our company’s products and services.
In addition to providing LAESI DP-1000 instruments to bioanalytical laboratories worldwide, the company recently announced the opening of its Mass Spectrometry Imaging Center (MSIC) in Morgantown, WV, where biologists can directly access LAESI’s powerful bioanalytical capabilities and Protea’s scientific team for their research projects.
Protea’s LAESI (Laser Ablation Electrospray) technology allows two and three dimensional distribution profiles of biomolecules in biological samples for unambiguous drug / target interaction studies, as well as the study of biodynamics directly from living cells. Using LAESI mass spectrometry, large numbers of biomolecules can be rapidly identified and spatially mapped to cell structures, tissues, and fluids.
A webinar replay of the presentation is available at: www.proteabio.com
More information about the Needham conference can be found at: http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx.
